Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- MSD to Promote Joint Detailing by Sales Units Specialized in Different Therapeutic Fields: Vice Pres. Kotani
November 22, 2012
- Bayer to Initiate PIII Study of Xarelto for Prevention of MACE in Patients with CAD/PAD, Considers Study in Japan as Well
November 22, 2012
- Japanese Ethical Drug Market Shows Negative Growth in July-September for the First Time in 7 Quarters: IMS Japan
November 21, 2012
- Nexium Dominates HP and GP Markets from October: Rep Track Survey
November 21, 2012
- Sales Up 20% for 3 Major Generic-Only Companies in 1st Half of FY2012
November 21, 2012
- RaQualia to Obtain Substance Patent for APA in Japan
November 20, 2012
- Daiichi Sankyo Files Inavir for Prevention of Influenza Infection
November 20, 2012
- Kyowa Kirin President Hanai Indicates Certain Level of Understanding for “Health Economic Evaluation”
November 20, 2012
- Plan to Expand AZ-BMS Partnership in Diabetes “on Track”: AZ K.K. Pres. Hudson
November 19, 2012
- Toho HD Confident of Achieving 1% Full-Year Operating Profit Rate in Wholesale Business: Vice-President Kono
November 19, 2012
- Novartis to Revamp Marketing Structure in CNS Field, Shift from SOV
November 19, 2012
- Sawai Aims at Top Positions for New Products in Mediceo Utilizing Mediceo’s ARs: President Sawai
November 19, 2012
- E Keppra Grabs 20% Share of Domestic Anti-Epileptic Drug Market; Sales Growing Rapidly
November 19, 2012
- Medical System Network, Hanshin Dispensing Pharmacy to Set Up New Company for Drug Purchase Next April
November 16, 2012
- Nichi-Iko Aims to Initiate PI Study of Herceptin Biosimilar in FY2013: President Tamura
November 16, 2012
- 3 More Companies Temporarily Discontinue Marketing Generics Due to GMP Non-Compliance at South Korean Supplier
November 16, 2012
- Acquisitions Support Recovery in Leading Domestic Drug Makers’ Overseas Sales Ratio to 37%
November 15, 2012
- Shionogi, ViiV Obtain Favorable Results in 3rd PIII Clinical Trial for Dolutegravir
November 15, 2012
- Healthcare Sales Soar 4.4% with Expansion of Abilify in Japan: Otsuka HD
November 15, 2012
- OrphanPacific to Initiate New Business Model “Contract MAH for Overseas Pharma”
November 15, 2012
ページ
As many as 47 new drug candidates are expected to win approval or secure NHI price listing in Japan in…
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…